Four Consecutive Years
The Shenzhen Plastic and Cosmetic Surgery Industry Association recently announced the results of the "2025 Quality, Safe, and Trusted Medical Aesthetics Institutions (Service Providers)" selection. Shenzhen Medgen Life Science Co., Ltd. once again received the "2025 Quality, Safe, and Trusted Medical Aesthetics Service Provider" award, recognized for its technological strength in regenerative medical materials and its reputation for product quality.
Corporate Strength
Founded in 2017, Medgen focuses on cutting-edge fields including biomaterials, regenerative engineering, and translational medicine. As a national-level high-tech enterprise integrating R&D and manufacturing, the company operates a regenerative materials production base and R&D center compliant with ISO 13485 and GMP standards, providing a solid hardware and system foundation for product quality.
Built on two core technology platforms — "hydroxyapatite regenerative product development" and "biomedical collagen protein technology" — the company has developed product lines including bone graft materials, collagen, PRP, and ECM acellular dermal matrix, covering orthopedics, sports medicine, oral surgery, and medical aesthetics.
Currently, pre-filled bone graft material (BoneSwift™), oral bone graft material (PoroGraft®), and a PRP preparation device have received market approval, while additional novel regenerative repair materials are in active development.
Quality First
Upholding the corporate spirit of "self-improvement and pioneering innovation," Medgen applies medical-grade production standards to its medical aesthetics materials. From raw material selection and process control to finished product inspection, the entire process is governed by a rigorous quality management system to ensure product safety and efficacy.
This uncompromising pursuit of quality enables Medgen's products to meet the demanding requirements of clinical applications in orthopedics and sports medicine while simultaneously providing the medical aesthetics industry with truly "trusted" regenerative material solutions — earning the confidence of both downstream institutions and end consumers.
Outlook
Looking ahead, Medgen will continue to deepen its regenerative repair materials R&D, working alongside industry peers to promote standardized and professional medical aesthetics services. The company will translate the sustainable development strategies of "Healthy China" and the "beauty economy" into action, firmly pursuing a path of compliance, professionalization, and high-quality development, contributing its technological capabilities to the healthy growth of the medical aesthetics industry in Shenzhen and beyond.